Hofheinz RD et al. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Critical reviews in Oncology/Hematology 2017; 144: 102-113.
Hofheinz RD, Deplanque G, Komatsu Y et al. Recommendations for the prophylactic management of skin reaction induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Oncologist 2016; 21: 1483-1491
Ocvirk J. Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream. Radiol Oncol 2010; 44: 265-266
Eaby-Sandy B, Grande C, Hallquist Viale P. Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors. J Adv Pract Oncol 2012; 3: 138-150
Pinto c, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E. Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. The Oncologist 2011; 19: 1079-1095.
Hofheinz RD, Lorenzen S et al. EVITA—a double-blind, vehicle-controlled,randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Annals of Oncology 29: 1010–1015, 2018.
GAISER, Maria R., et al. Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score. Cancer Medicine, 2019.